Výsledky vyhledávání - Karthick Vishwanathan

  • Zobrazuji výsledky 1 - 12 z 12
Upřesnit hledání
  1. 1
    Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label

    Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label Autor Venkatesh Pilla Reddy, Michael L. Walker, Pradeep Sharma, Peter Ballard, Karthick Vishwanathan

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer

    Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer Autor Kathryn H. Brown, Craig Comisar, Han Witjes, John Maringwa, Rik de Greef, Karthick Vishwanathan, Mireille Cantarini, Eugène Cox

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, <scp>ACP</scp>‐5862, Using a <scp>Physiologically‐Based Pharmacokinetic</scp> Modeling Approach

    Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, <scp>ACP</scp>‐5862, Using a <scp>Physiologically‐Based Pharmacokinetic</scp> Modeling... Autor Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph A. Ware, J. Greg Slatter, Nidal Al‐Huniti

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer

    Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer Autor Martin Johnson, Yu‐Wei Lin, Henning Schmidt, Mikael Sunnåker, Eline van Maanen, Xiangning Huang, Yuri Rukazenkov, Helen Tomkinson, Karthick Vishwanathan

    Vydáno 2025
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    A PET study in healthy subjects of brain exposure of <sup>11</sup>C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer

    A PET study in healthy subjects of brain exposure of <sup>11</sup>C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer Autor Andrea Varrone, Katarina Varnäs, Aurelija Jučaitė, Zsolt Cselényi, Peter Johnström, Magnus Schou, Ana Vázquez‐Romero, Mohammad Mahdi Moein, Christer Halldin, Andy Brown, Karthick Vishwanathan, Lars Farde

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

    Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model Autor Yuri Kosinsky, Lulu Chu, Millie Shah, Karthick Vishwanathan, Connie A. Larsson, Andrew Bloecher, Brandon S. Willis, Hannah Dry, Kirill Peskov, Joseph A. Ware, Andrew Mortlock, Gabriel Helmlinger

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

    Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis Autor Myung‐Ju Ahn, Chao‐Hua Chiu, Ying Cheng, Ji‐Youn Han, Sarah B. Goldberg, Alastair Greystoke, Jeffrey Crawford, Yanqiu Zhao, Xiangning Huang, Martin Johnson, Karthick Vishwanathan, James Yates, Andy Brown, Ariadna Mendoza‐Naranjo, Tony Mok

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

    TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer Autor Geoffrey R. Oxnard, J.C.-H. Yang, Helena A. Yu, Seung‐Whan Kim, Hideo Saka, Leora Horn, Kōichi Goto, Yuichiro Ohe, Helen Mann, Kenneth S. Thress, Melanie M. Frigault, Karthick Vishwanathan, Dana Ghiorghiu, Suresh S. Ramalingam, Myung‐Ju Ahn

    Vydáno 2020
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

    The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib Autor Karthick Vishwanathan, Paul A. Dickinson, Karen So, Karen Thomas, Yuh‐Min Chen, Javier de Castro, Anne‐Marie C. Dingemans, Hye Ryun Kim, Joo‐Hang Kim, Matthew Krebs, James Chih‐Hsin Yang, Khanh Bui, Doris Weilert, R. Donald Harvey

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers

    Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers Autor Jorge E. Cortés, Kenji Tamura, Daniel J. DeAngelo, Johann S. de Bono, David Lorente, Mark D. Minden, Geoffrey L. Uy, Hagop M. Kantarjian, Lisa S. Chen, Varsha Gandhi, Robert Godin, Karen Keating, Kristen McEachern, Karthick Vishwanathan, J. Elizabeth Pease, Emma Dean

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

    Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study Autor James Chih‐Hsin Yang, Sang-We Kim, Dong‐Wan Kim, Jong Seok Lee, Byoung Chul Cho, Jin-Seok Ahn, Dae H. Lee, Tae Min Kim, Jonathan W. Goldman, Ronald B. Natale, Andy Brown, Barbara Collins, Juliann Chmielecki, Karthick Vishwanathan, Ariadna Mendoza‐Naranjo, Myung‐Ju Ahn

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

    Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases Autor Gregory S. Basarab, Günther Kern, John McNulty, John P. Mueller, Kenneth Lawrence, Karthick Vishwanathan, Richard A. Alm, Kevin Barvian, P. Doig, Vincent Galullo, Humphrey Gardner, Madhusudhan Gowravaram, Michael D. Huband, Amy Kimzey, Marshall Morningstar, Amy Kutschke, Sushmita D. Lahiri, Manos Perros, Renu Singh, Virna Schuck, Rubén Tommasi, Grant K. Walkup, Joseph Newman

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: